copies/mL. Other relevant laboratory results included an IL-6 > 29.7 pg/mL (normal value < 17.4), positive results on hepatitis B core antibody and hepatitis surface antibody tests, and negative results on hepatitis B surface antigen and hepatitis B viral DNA tests.
On biopsy, the bone marrow was normal with trilineage maturation. A lymph node biopsy revealed pathologic fi ndings consistent with MCD. Th ere were numerous follicles, some of which had penetrating small vessels (Figure 1a) . Lymphocytes in the mantle zone were arranged in concentric circles (so called "onion skinning"). Th ere was prominent interfollicular vascular proliferation with a pronounced plasma cell infi ltrate. Th e plasma cells expressed IgM and were polytypic by fl ow cytometric analysis and immunohistochemistry stains. Large cells with vesicular nuclei, prominent nucleoli, and amphophilic cytoplasm (plasmablasts) were present in the mantle layer and interfollicular areas. Focal clusters of these plasmablasts encroached on the germinal centers, forming so-called microlymphomas (Figure 1b) . HHV-8 was detected in the plasmablasts by in situ hybridization (Figure 1c) . A test for Epstein Barr virus-encoded small RNA (EBER) was negative. Th e lesion was considered to be HHV-8-associated MCD with microfoci of large cell lymphoma (microlymphomas).
Th e patient underwent six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP21) with growth factor support and continues to do well clinically. previously pathologic lymph nodes were normal in size. A PET scan done after completion of chemotherapy showed no residual disease. Th e patient continues retroviral therapy, and his HIV load is now undetectable. He is also being treated with abacavir/lamivudine for hepatitis B. A follow-up HHV-8 DNA by polymerase chain reaction was <1000 copies/mL. An IL-6 level was not repeated.
DISCUSSION
MCD is a rare, aggressive lymphoproliferative disorder that has a poor prognosis usually requiring systemic chemotherapy (1) (2) (3) (4) . MCD is commonly associated with HHV-8, an oncogenic herpesvirus, and is most often seen in immunosuppressed individuals infected by HIV type 1 (5) . Th e pathologic features of MCD strongly suggest a chronic antigen stimulation response, and HHV-8 has been found in virtually all cases of HIV-related MCD (6) . Th e presentation is usually nonspecifi c, resulting in an extensive diff erential diagnosis that often results in a delay of the diagnosis. Th e diagnosis is established on the clinical presentation of a lymphoproliferative disorder with evidence of multisystem involvement and the classic histopathology on a lymph node biopsy as described in the case presentation. Th ose with MCD may develop lesions described previously as microlymphomas composed of plasmablasts. Th e plasmablasts typically reveal lambda light chain restriction but do not harbor somatic mutations in the rearranged immunoglobulin genes. With disease progression, frank plasmablastic lymphomas may develop (7, 8) . It is interesting that these lymphomas are monoclonal, although the immunoglobulin genes remain unmutated (8) . Compared with HIV-infected patients without MCD, those with MCD have a 15-fold increased risk of non-Hodgkin lymphomas, with the most common subtype of MCD being HHV-8-positive plasmablastic lymphoma.
It has long been recognized that the features of MCD strongly suggest a secondary antigen proliferation response. It has been hypothesized that an infectious agent could be the triggering antigen for the introduction of a pathological process via abnormal IL-6 production, unregulated by a defective immune system (9, 10) . Th e IL-6 level in our case was elevated. HIV itself is highly replicated in lymphoid tissue and could play a role in the persistent B-cell activation (11) . Th e IL-6 signaling pathway may play an important role in driving HHV-8-infected naive B cells to diff erentiate into plasmablasts (12) . HHV-8 encodes for viral IL-6, an IL-6 homologue that has many of the biological activities of human IL-6 (13). Furthermore, elevated levels of IL-6 correlate with clinical symptoms and HHV-8 viral load (10, 12) .
While the survival of patients with HIV and coexistent MCD and non-Hodgkin lymphoma is generally poor, with a median survival of 48 months (14, 15) , there are exceptions. Researchers have documented success in treating patients with HIV-associated MCD with antivirals (16) and in treating AIDS-related lymphoma patients with highly active antiretroviral therapy, rituximab, and chemotherapy (17) . Hopefully, the prospects of HIV-infected patients with HHV-8-associated MCD and plasmablastic lymphoma will also improve. 
